Chronic kidney disease (CKD) causes progressive loss of kidney function over time. 1 in 10 people have CKD worldwide, and the number of deaths due to CKD have doubled since 1990, reaching almost one million in 2013.1 Today, there are a limited number of therapies that can halt or modify disease progression. But this doesn’t reflect tremendous amount of active research and investigation underway in this field – or how radically different the future could look like for people with CKD and their treating physicians.
The American Society of Nephrology (ASN) Kidney Week Annual Meeting kicks off this week. As the largest nephrology congress in the world, it will bring together more than 13,000 kidney professionals from across the globe for discussions on areas of unmet need and potential near term and long-term innovations to treat nephrological diseases.
I’m really proud to share AstraZeneca is presenting or publishing various abstracts at ASN Kidney Week in 2018. These abstracts cover a wide range of science that address multiple points on the continuum of CKD care, ranging from complications in CKD to disease modification. I hope for a future where an early diagnosis means early action can be taken to manage the disease, to prevent future complications.
I have attended ASN Kidney Week for the last 6 years as a delegate from AstraZeneca, and I must admit that our growth at this congress year after year has been incredible. It reflects our growing investment in renal science, and our commitment to this area. We will continue to demonstrate that commitment through our exploration, research and development. I am energised by how far we’ve come in this space.
For those attending the congress, I wish you a successful meeting.
1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015; 385(9963):117–71.
Veeva ID: Z4-13407
Date of next review: October 2020